Erba, H. P., Kantarjian, H., Claxton, D. F., Arellano, M., Lyons, R. M., Kovacsovics, T. J., … Faderl, S. (2008). Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy. In BLOOD (Vol. 112, pp. 209–209). San Francisco, CA: AMER SOC HEMATOLOGY.

Erba, Harry Paul, Hagop Kantarjian, David F. Claxton, M. Arellano, Roger M. Lyons, Tibor J. Kovacsovics, Janice Gabrilove, Stephen Eckert, Rekha Abichandani, and Stefan Faderl. “Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.” In BLOOD, 112:209–209. AMER SOC HEMATOLOGY, 2008.

Erba HP, Kantarjian H, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, et al. Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy. In: BLOOD. AMER SOC HEMATOLOGY; 2008. p. 209–209.

Erba, Harry Paul, et al. “Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, 2008, pp. 209–209.

Erba HP, Kantarjian H, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Abichandani R, Faderl S. Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy. BLOOD. AMER SOC HEMATOLOGY; 2008. p. 209–209.